产品
编 号：F751651
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2375240-92-7
产品详情
生物活性：
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis.
体内研究：
Efruxifermin (0-100 mg/kg, SC, Once weekly, for 4 or 26?weeks) reduces body weight gain of Sprague Dawley rats in a dose-dependent manner.Animal Model:Male and female Sprague Dawley rats
Dosage:0, 1, 10, 30, 100 mg/kg
Administration:Subcutaneous injection, Once weekly, for 4 or 26?weeks
Result:Significantly reduced body weight gain after 4 and 26?weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged.
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis.
体内研究：
Efruxifermin (0-100 mg/kg, SC, Once weekly, for 4 or 26?weeks) reduces body weight gain of Sprague Dawley rats in a dose-dependent manner.Animal Model:Male and female Sprague Dawley rats
Dosage:0, 1, 10, 30, 100 mg/kg
Administration:Subcutaneous injection, Once weekly, for 4 or 26?weeks
Result:Significantly reduced body weight gain after 4 and 26?weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备